Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	<b>OF CHANGES</b>	IN BENEFICIAL	OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Richard Ronald</u>						2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ]									tionship of Reporting all applicable) Director		g Person(s) to Issu 10% Ow		
(Last) (First) (Middle) 400 PROFESSIONAL DR, SUITE 400						3. Date of Earliest Transaction (Month/Day/Year) 12/12/2017									Officer below)	(give title		Other (s below)	specify
(Street) GAITHERSBURG MD 20879 (City) (State) (Zip)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indivine)						
		Tab	le I - I	Non-Deri	ivativ	e Sec	curit	ies A	cquire	ed, D	isposed c	of, or B	enefici	ally (	Owned				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye						Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			Beneficia		es For ially (D) Following (I) (		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	ction(s)			(Instr. 4)
Common Stock 12/12/201				2017	17		M		23,681(1)	A	\$10.0	\$10.64		47,091		D			
Common Stock 12/12/201			2017	17		S		23,681(1)	D	\$45.02	45.0245 <sup>(2)</sup>		23,410		D				
		-	Table								sposed of, , converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year) 8			Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e Exer ation D h/Day/		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		Do	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amour or Number of Shares	er					
Employee Stock Option (Right to	\$10.64	12/12/2017			M			23,681	(4	4)	05/21/2019	Common Stock	23,68	1	\$0	0		D	

## **Explanation of Responses:**

- $1. \ The \ transaction \ reported \ in \ this \ Form \ 4 \ was \ effected \ pursuant \ to \ a \ Rule \ 10b5-1 \ trading \ plan \ adopted \ by \ Mr. \ Richard.$
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$45.00 to \$45.17, inclusive.
- 3. Consists of an option granted under the company's stock incentive plan as amended and restated.
- 4. The option grant is fully vested.

/s/ Eric Burt, Attorney-in-fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.